Experience

Davis Polk advised Penumbra, Inc. on its SEC-registered initial public offering of 4,600,000 shares of common stock for an aggregate price to the public of approximately $138 million,…

Davis Polk advised the underwriters, in connection with an SEC-registered offering by Seattle Genetics, Inc. of 13,463,415 shares of common stock, which includes 1,756,097 shares of common…

Davis Polk advised the underwriters, in connection with the SEC-registered offering by Biogen Inc. of $1.5 billion principal amount of 2.900% senior notes due 2020, $1.0 billion principal…

Davis Polk advised the joint book-running managers in connection with the $138 million initial public offering of common stock of Global Blood Therapeutics, Inc. Global Blood’s common stock…

Davis Polk advised the joint book-running managers on an SEC-registered offering by Celgene Corporation of $8.0 billion aggregate principal amount of notes. The notes were issued in…

Davis Polk advised the underwriters in connection with the $183.9 million initial public offering of Aimmune Technologies, Inc. Aimmune Therapeutics sold 11,499,999 shares of its…

Davis Polk advised the joint book-running managers in connection with the $207 million SEC-registered follow-on offering of common stock of Atara Biotherapeutics, Inc. The common stock…

Davis Polk advised the joint book-running managers in connection with the $180 million initial public offering of 10,000,000 shares of common stock of Natera, Inc. Natera’s common…

Davis Polk advised Capio AB (publ) on its initial public offering and listing of shares on NASDAQ Stockholm. Assuming full exercise of the overallotment option, 52,934,872 shares were sold…

Davis Polk advised the initial purchasers in connection with a Rule 144A/Regulation S offering by Hologic, Inc. of $1 billion aggregate principal amount of its 5.250% senior notes due 2022…